Introduction Chronic hypersecretion of the 37 amino acid amylin is common in type 2 diabetics (T2D). Recent studies implicate human amylin aggregates cause proteotoxicity (cell death induced by misfolded proteins) in both the brain and the heart. Objectives Identify systemic mechanisms/markers by which human amylin associated with cardiac and brain defects might be identified. Methods We investigated the metabolic consequences of amyloidogenic and cytotoxic amylin oligomers in heart, brain, liver, and plasma using non-targeted metabolomics analysis in a rat model expressing pancreatic human amylin (HIP model). Results Four metabolites were significantly different in three or more of the four compartments (heart, brain, liver, and plasma) in HIP rats. When compared to a T2D rat model, HIP hearts uniquely had significant DECREASES in five amino acids (lysine, alanine, tyrosine, phenylalanine, serine), with phenylalanine decreased across all four tissues investigated, including plasma. In contrast, significantly INCREASED circulating phenylalanine is reported in diabetics in multiple recent studies. Conclusion DECREASED phenylalanine may serve as a unique marker of cardiac and brain dysfunction due to hyperamylinemia that can be differentiated from alterations in T2D in the plasma. While the deficiency in phenylalanine was seen across tissues including plasma and could be monitored, reduced tyrosine was seen only in the brain. The 50 % reduction in phenylalanine and tyrosine in HIP brains is significant given their role in supporting brain chemistry as a precursor for catecholamines (dopamine, norepinephrine, epinephrine), which may contribute to the increased morbidity and mortality in diabetics at a multisystem level beyond the effects on glucose metabolism.
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Introduction
Amylin, or islet amyloid polypeptide, is a 37 amino acid hormone, co-secreted with insulin from b-cells in the pancreatic Islets of Langerhans. Since its discovery in 1986, research identifying amylin's regulatory effects on nutrient fluxes, satiation, and on the regulation of insulin and pancreatic beta cells have been reported (Hay et al. 2015) . In addition to its emerging physiological roles, chronic hypersecretion of amylin is an emerging concern as it is common in pre-diabetic and obese humans (Despa et al. 2012 (Despa et al. , 2014 . Recent studies have demonstrated that human amylin aggregates in vivo to cause proteotoxicity (cell death induced by misfolded proteins) in both the brain and the heart (Despa et al. 2012 (Despa et al. , 2014 Srodulski et al. 2014) .
These studies have redefined the relationship between type II diabetes and neurodegenerative disease. As the most common form of dementia, Alzheimer's disease is characterized by the accumulation of extracellular beta amyloid (Ab) peptide aggregates and intracellular hyperphosphorylated tau protein (Verdile et al. 2015) . Recent studies have identified amylin oligomers and plaques in the temporal lobe gray matter from diabetic patients, but not controls (Jackson et al. 2013) . Interestingly, while amylin accumulation lead to amyloid formation independent of amyloid beta deposition, tissues infiltrated by amylin occasionally mixed with amyloid beta protein, the typical pathogenic lesion in Alzheimer's disease (Jackson et al. 2013) . Amylin infiltration in these patients were widespread, evidenced by increased interstitial space, vacuolation, spongiform changes, and capillaries bent at amylin accumulation sites without evidence of synthesis in the brain (Jackson et al. 2013 ). These findings have led to the hypothesis that human amylin has a role at the interface between metabolic and neurodegenerative disorders which are widely underestimated (Lutz and Meyer 2015) .
In the present study, we investigated the metabolic consequences of amyloidogenic and cytotoxic amylin oligomers and diabetes in the multiple organs applying non-targeted metabolomics analysis to a recently created rat model expressing pancreatic human amylin (HIP model). Since rodent amylin has been found to be uniquely non-amyloidogenic and non-cytotoxic in contrast to human amylin, rats expressing human amylin in the pancreas (HIP) have previously been utilized to elucidate that oligomerized amylin migrates to most organs, including the heart and brain (Despa et al. 2014; Lambert et al. 2015; Srodulski et al. 2014 ). Compared to littermate wildtype HIPTg? rats, the HIP rats have defects in the pancreas over time, leading to diabetes and brain/heart dysfunction secondary to the accumulation of oligomerized amylin, including large deposits of [50 microns in the brain (Srodulski et al. 2014) . The hyperamylinemia-induced oligomerized amylin further mediated activation of inflammation, leading to neurologic defects manifesting as reduced exploratory drive, impaired recognition memory, and the lack of ability to improve rotarod performance (an assay of body balance) (Srodulski et al. 2014) . Cardiac defects are seen in parallel, Na
? influx significantly larger in HIP myocytes compared to wildtype HIPTg? controls, resulting in arrhythmogenesis and oxidative stress (Lambert et al. 2015) . To delineate how human amylin affects the heart, brain, and liver we performed non-targeted metabolomics on 12-month-old HIP rats along with non-targeted analysis of plasma to identify if the metabolic changes seen in tissues are paralleled in the circulation as biomarkers of disease.
Materials and methods

Transgenic HIP rat model
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by the Institutional Animal Care and Use Committees at University of Kentucky. Male HIP rats at 1 year of age were used in the present study and are Sprague-Dawley rats expressing human amylin in pancreatic b-cells. This model was previously used to study complications of type 2 diabetics (T2D) associated with amylin deposition in myocardium (Despa et al. 2012; Erickson et al. 2013 ) and brain (Srodulski et al. 2014) . Age-and gender-matched wild type littermates (wildtype HIPTg? ) do not accumulate pancreatic or peripheral amylin and served as controls. The tissue assayed and the glucose determinations in the current study are exclusive newly generated data.
Metabolomics determination by GC-MS instrumentation
Cardiac tissue was flash frozen in a liquid nitrogen cooled biopress, weighed (25-50 mg wet weight), then placed in buffer (50 % acetyl-nitrile, 50 % water, 0.3 % formic acid) at a standard concentration of 25 mg/475 mcl buffer then fully homogenized on ice for 10-25 s and placed on dry ice/stored at -80°C. Samples were then analyzed by GC/MS, as previously described (Banerjee et al. 2015) . The raw, transformed, and sorted data used for each of the three comparisons in the metabolomics analyses can be found in Supplemental Table 1 . Up to three missing values per group were imputed using lowest value in the same group, with groups missing four or more excluded from the analysis. In groups where the analyte was missing in all members, a value of one was imputed for statistical analysis, with their fold change interpreted with caution as indicated in Figs. 1, 2, 3, and 4 (*, e.g. Inosine 5 0 monophosphate in Fig. 1a ). All data used in this analysis has been archived in the UCSD Metabolomics Workbench (http://www.metabolomicsworkbench. org/), accession #PR000279.
Metabolomic statistical analyses
Metaboanalyst (v3.0) run on the statistical package R (v2.14.0) used metabolite peaks areas (as representative of concentration) (Xia et al. 2009 (Xia et al. , 2015 . These data were first analyzed by an unsupervised principal component analysis (PCA), which identified the presence of the human islet amyloid polypeptide (hIAPP)-amylin as the principal source of variance. The metabolites that best differentiated the groups were then individually tested using the Univariate analysis of individual component by t test (Metaboanalyst v 3.0), and then the t test significant metabolites were matched to metabolomics pathways using the pathway analysis and enrichment analysis features in Metaboanalyst 3.0. To detect systemic metabolic signature of amylin, a one-way analysis of variance (ANOVA) across the eight tissues and genotypes was performed (wildtype HIPTg? heart, HIPTg? heart, wildtype HIPTg? plasma, and HIPTg? plasma) using Metaboanalyst v3.0, including both false discovery rate and significance (p). Only metabolites identified and detected in all groups were included in the one-way ANOVA. If four or more values of each metabolite were missing in a given group, the entire metabolite was removed from the analysis. Only metabolites significantly altered in two or more organs were plotted to show systemic alterations induced by amylin. Data used in this study are available in Supplemental Table 1.13. Heat maps were generated using the GENE-E software (http://www. broadinstitute.org/cancer/software/GENE-E/index.html). All data is shown as mean ± SEM, unless otherwise indicated.
Validation study
In order to differentiate amylin metabolic effect from diabetic metabolic signature, we compared our results with published non-targeted metabolomic datasets obtained from type 2 diabetic hearts (Kouzu et al. 2015) . PubMed was searched using the terms ''Metabolomics'' ''heart'' ''type 2 diabetes'' and ''rat'', resulting in two articles. We chose the dataset from Kouzu et al. 2015 for its similarity of T2D and baseline controls clinically. Metabolites identified in both our study and the Kouzu et al. 2015 
Results
Blinded non-targeted metabolomics analysis of cardiac samples identified and named 100 metabolites (Fig. 1a) . Using an unsupervised PCA analysis, the HIP cardiac metabolites separated into distinct population, with 47.7 % of the differences accounted for by principal component 1 (Fig. 1b) . T test analysis of these cardiac HIP metabolites identified 45 as significantly different (p \ 0.05) (Fig. 1c (Fig. 1c) . Pathway analysis enrichment of the t test significant metabolites revealed the highest enrichment (approximately sevenfold enrichment) in: (1) protein biosynthesis; (2) alpha-linolenic and linoleic acid metabolism; (3) Glycolysis; and (4) phenylalanine and tyrosine metabolism (Supplemental Fig. 1A ). Analysis against location based enrichment identified approximately tenfold enrichment in ''Basal Ganglia'' metabolites, then lysosome, mitochondria, and skeletal muscle (Supplemental Fig. 1B) .
Blinded non-targeted metabolomics analysis of HIP brain samples identified and named 144 metabolites (Fig. 2a) . Unsupervised PCA analysis identified overlap between the HIP and wildtype HIPTg? brain metabolite signature (Fig. 2b) , with 30 t test significant metabolites identified (Fig. 2c) . Similar to the cardiac metabolomics findings, the pathway enrichment analysis identified enrichment in the protein synthesis pathway (Supplemental Fig. 2A ). In addition, gluconeogenesis, phenylalanine/tyrosine metabolism, and the pentose metabolism pathways were highly enriched (greater than or equal to fourfold enrichment) (Supplemental Fig. 2A ). Like the heart, pathway analysis for location enrichment found a [15-fold enrichment in ''Basal Ganglia'' metabolites, along with muscle and Fig. 2B ). Interestingly, analysis against CSF metabolite pathways identified an eightfold enrichment in ''2-methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency'' and ''phenylketonuria'' (Supplemental Fig. 2C ).
Blinded non-targeted metabolomics analysis of HIP liver samples identified multiple metabolites that were not present in wildtype HIPTg? control rats, including cystine, 5-aminovaleric acid, cytidine-5 0 -monophosphate, and phytol along with elevated propylene glycol (Fig. 3A) . These metabolites demonstrated distinct signatures by PCS analysis (Fig. 3B) brain t test significant metabolites and indicating fold change and false discovery rates (FDR) for each metabolite. N = 10/group (Fig. 3C ). Pathway analysis revealed that alpha linolenic acid and linoleic acid metabolism, gluconeogenesis, and glycerolipid metabolism were the highest enriched (greater than threefold, Supplemental Fig. 3A) . Location enrichment analysis identified ''Basal Ganglia'', as in the brain prior, enriched approximately sevenfold (Supplemental Fig. 3B ).
In contrast, the differences in the non-targeted metabolomics analysis of parallel HIP plasma (Fig. 4a) overlapped by PCA analysis (Fig. 4b ) and had only 16 t test significant metabolites (Fig. 4b) . As identified in the heart and brain, protein biosynthesis was the most significantly enriched pathway (approximately sevenfold), with biotin metabolism was also highly enriched [15-fold (Supplemental Fig. 4 To understand the metabolic signatures identified across the different organ systems, we next performed an ANOVA comparing heart, brain, liver, and plasma in HIP and wildtype rats (8 groups total). With a false discovery rate (FDR) \1 9 10 -9 , we identified that fumarate (Fig. 6a) , phenylalanine (Fig. 6b) , a-monstearin (Fig. 6c) , and uracil (Fig. 6d) Fig. 4 Non-targeted metabolomics of plasma in human amylin producing rat models (HIP rats). a Heat map of metabolites identified by non-targeted GC/MS analysis of plasma. b Principal components analysis. c Heat map comparing HIP to wildtype HIPTg? plasma t test significant metabolites and indicating fold change and false discovery rates (FDR) for each metabolite. N = 10/group decreased in the plasma as well, making it the only metabolite DECREASED in all four compartments tested in the HIP model (Fig. 6b) . In this same ANOVA analysis, eight additional metabolites were significantly elevated in at least two compartments (Table 1) , with lysine being the only one additionally found in plasma. While the ANOVA analysis across all four organs allowed the direct comparison of amino acids identified in all organs, there were multiple amino acids that were not detected in at least one organ (Supplemental Table 2 , primarily right half of table). Significant alterations were seen in glutamic acid (heart and Liver), ornithine, cysteine and cystine (Liver only) (Supplemental Table 2 ).
One of the complexities of the HIP model studied here is the fact that while the HIP rats are not initially diabetic, they develop diabetes as the proteotoxicity of the human amylin kills the pancreatic beta cells (Table 2) . Distinguishing the metabolic signatures of the type 2 diabetes from the amylin proteotoxicity component was what we next addressed using a published non-targeted metabolomics data set in a type 2 diabetes rat model recently published (Kouzu et al. 2015) . Using an ANOVA analysis of the cardiac HIP (and strain-matched wildtype) significant metabolites with the recently published T2D (and strain-matched wildtype) significant metabolites revealed that both models had similar significant decreases in glycine (HIP vs. T2D p [ 0.05; HIP vs. wildtype HIPTg? p = 0.001, T2D vs wildtype T2D p = 0.028) and similar significant increases in leucine (Fig. 6, indicated with  boxes) . This confirms the expected overlap of the HIP and T2D models. Interestingly, we identified eight metabolites that were significantly different in the HIP heart, but not in the T2D heart: including pyruvate, malate, citrate, fumarate, urea, glycerol-1-phosphate, fructose-6-phosphate, glucose-6-phosphate, and hypoxanthine (Fig. 6a , indicated by *). Significantly altered amino acids found in the HIP heart, but not in the T2D heart, including: lysine, alanine, tyrosine, phenylalanine, serine, threonine, glutamic acid, and valine (Fig. 6b , indicated by *). Uniquely, HIP heart had significantly INCREASED fructose-6-phosphate and glucose-6-phosphate, which was not seen in the T2D hearts (Fig. 6a ). The HIP heart had significantly DECREASED alanine, tyrosine, and phenylalanine in contrast to the significantly INCREASED levels of these amino acids in the T2D hearts (Fig. 6b) .
Discussion
In contrast to previous studies illustrating alterations in amino acid levels in just the diabetic heart, the current studies demonstrate that these changes occur systemically across multiple organs (heart, brain, liver, plasma, Fig. 6 , Supplemental Table 3 ). Protein biosynthesis was the highest enriched pathway in the HIP heart and brain, with a greater than fivefold enrichment by pathway analysis (Supplemental Figs. 1, 2) . Alterations in phenylalanine metabolism and aminoacyl-tRNA biosynthesis were specifically identified as affected (Supplemental Fig. 5A,  D) . These studies build upon sparse reports of decreased phenylalanine in diabetic hearts (Rampersad and Wool 1965) , increased protein degradation in muscle (Ashford and Pain 1986) , and alterations in mitochondrial protein synthesis (Boirie et al. 2001 ). The present study illustrates that changes in tyrosine metabolism are affected more widely, including tyrosine decreases in heart (Fig. 5a ), phenylalanine decreases in heart and Liver and increased fumarate, a degradation product of tyrosine/phenylalanine metabolism (Figs. 5a, 6a) . Evidence for increased protein degradation comes from the finding that there is increased tyrosine/phenylalanine degradation product fumarate (Figs. 5a, 6a) , and the finding that urea and intermediates of the urea cycle are increased (Figs. 5b, 6b) . As systemic protein degradation is a major up-regulator of urea cycle in Table 2 Glucose levels at harvest in samples used to assay heart, brain, liver, and plasma in the HIP and control animals WT rat heart (8 samples)
WT rat brain (10 samples)
WT rat plasma (10 samples)
WT rat liver ( diabetes (Jorda et al. 1982; Li et al. 2010; Schutz 2011 ), the present findings may demonstrate a relationship here in linking amylin and diabetes with the urea cycle changes identified here. Given the close connection between increased protein catabolism, morbidity and increased hospital stay and mortality, the connection between diabetes in chronic and acute diseases may lie in processes beyond the effects on glucose metabolism (Pasini et al. 2014 (Pasini et al. , 2013 . The comparison of non-targeted metabolomics found in the HIP rat heart compared to a strictly T2D model in the present study identified unique metabolomics alterations in the HIP heart not attributable to T2D (Supplemental Fig. 6 cycle metabolites (pyruvate and urea) and metabolites involved in gluconeogenesis (glycerol-1-phosphate, fructose-6-phosphate, and glucose-6-phosphate) (Supplemental Fig. 6A ). HIP hearts exhibited significant alterations in amino acids, with 5 being significantly DECREASED (lysine, alanine, tyrosine, phenylalanine, serine) and 1 INCREASED (valine) compared to T2D (Supplemental Fig. 6B ). This contrasts with the significantly INCREASED phenylalanine reported in diabetics versus controls in multiple recent studies (Kouzu et al. 2015; Tillin et al. 2015; Wurtz et al. 2015) . The HIP rats at 1 year exhibited this significant decreases across all four tissues investigated, including plasma (Fig. 6 ). This illustrates that DECREASE phenylalanine may be worth following as it correlates with HIP induced cardiac and brain dysfunction, but unrelated to the presence of T2D.
The deficiency in phenylalanine and tyrosine in HIP brains (\0.50-fold vs. wildtype HIPTg? ) is significant given their role in supporting brain chemistry (Fig. 2) . Tyrosine (and its precursor phenylalanine) in the brain function as precursors for catecholamines (dopamine, norepinephrine, epinephrine) (Fernstrom 2007) . Deficiency in dopamine, requiring these metabolites, contributes to early visual dysfunction in experimental type 1 diabetes (Aung et al. 2014) . Other studies of experimental type 1 diabetes have demonstrated that brain phenylalanine is decreased by an average of 40 % throughout the entire brain, with a depressed influx of 35 %, suggesting these decreases are due to transport defects (Mans et al. 1987) . The detection of elevated brain ketones, such as beta-hydroxybutyric acid in HIP mice nearly fourfold, is not unexpected given their diabetic status (Fig. 2b) has been detected by MR spectroscopy in children with diabetic ketoacidosis (Wootton-Gorges et al. 2005) and in other rat models (Reusch et al. 2003) , which alters glucose metabolism, glutamine, glutamate, and GABA (Lapidot and Haber 2001) .
Interestingly, the alterations in the pentose phosphate pathway (PPP) that were identified in the brain in the current study (Fig. 2, i. e. glucose-6-phosphate elevated 4.7-fold, fructose-6-phosphate elevated 5.3-fold) have previously been seen in the brain in neurodegenerative diseases. Unlike most other cell types, neurons preferentially metabolize glucose using the PPP to maintain their anti-oxidant status. Inhibiting this pathway results in selective dopaminergic cell death leading to motor deficits resembling Parkinson's disease (Dunn et al. 2014) . In Parkinson's disease brain tissues, down-regulation of PPP enzymes and failure to increase antioxidant reserve is an early event in the pathogenesis of sporadic Parkinson's disease (Dunn et al. 2014) , which parallels findings of reduced pentose phosphate fluxes are reduced in amyloid beta protein precursor (AbetaPP) mice and Alzheimer's disease patients (Tiwari and Patel 2014) . Importantly, these alterations are not characteristic of cognitively normal diabetics. Since the hyperamylinemia modeled in the HIP model demonstrated neurodegenerative plaques (Srodulski et al. 2014 ), the present studies may offer mechanistic detail of amylin-driven pathology.
Similar to the metabolites found in the brain that were linked to hyperamylinemia-induced proteotoxicity, the identification of cystine uniquely in the HIP liver (Fig. 3) was interesting as it has been identified in previously studies as a potential biomarker of Alzheimer's disease (Gonzalez-Dominguez et al. 2015) . As an important metabolic intermediate in glutathione metabolism, cystine may offer clues to oxidative stress not previously reported in the liver. While its not surprising to see alterations in anti-oxidant systems in the HIP rats given the inflammatory nature of diabetes in general and in this model specifically (Srodulski et al. 2014) , the increased in the reduced 5-aminovaleric acid has been used to detect oxidative stress in atherosclerotic lesions by GC-MS (Pietzsch et al. 2004) .
Recent studies applying non-targeted metabolomics to hyperglycemic mothers during pregnancy identified increased circulating levels of fructose, pentilols, and hexitols (Scholtens et al. 2014) , similar to the significantly elevated hexitols (increased 3.9-and 2.1-fold, respectively), pentilols (increased 3.7-fold), and fructose (increased 2.3-fold) in the present study (Fig. 4b) . While the role of hexitol/pentitol metabolism in the pathophysiology of diabetes is not clear, it has been proposed to play a role in clinical observations in diabetic patients ingesting the glucose substitute xylitol (Makinen 2000) . A glycation product that has been found in neurofibrillary pathology of Alzheimer's disease lesion is hexitol, where hexitol-lysine adducts form in a distinct oxidative process acting in concert with Alzheimer's disease lesions (Castellani et al. 2001) . Together, elevated fructose, pentilols, and hexitols found in HIP plasma may offer insight in the pathogenesis of multiple organs affected by hyperamylinemia and diabetes.
Conclusions
HIP hearts had significant DECREASES in five amino acids (lysine, alanine, tyrosine, phenylalanine, serine) and one significantly INCREASED amino acids (valine), which were unique from a T2D rat model. Additionally, The HIP rats exhibited a significant decrease in phenylalanine across all four tissues investigated, including plasma. This contrasts with the significantly INCREASED circulating phenylalanine reported in diabetics versus controls in multiple recent studies (Kouzu et al. 2015; Tillin et al. 2015; Wurtz et al. 2015) . DECREASED phenylalanine may serve as a unique marker of cardiac and brain dysfunction due to hyperamylinemia that can be differentiated from alterations in T2D in the plasma.
The deficiency in phenylalanine and tyrosine in HIP brains (\0.50-fold vs. wildtype HIPTg? ) is significant given their role in supporting brain chemistry. Tyrosine (and its precursor phenylalanine) in the brain function as precursors for catecholamines (dopamine, norepinephrine, epinephrine). While the deficiency in phenylalanine was seen across tissues including plasma and could be monitored, reduced tyrosine was seen only in the brain. The alterations in the pentose phosphate pathway (PPP) identified in the HIP brain (elevated glucose-6-phosphate and fructose-6-phosphate) have previously been seen in the brain in neurodegenerative diseases. Unlike most other cell types, neurons preferentially metabolize glucose using the PPP to maintain their anti-oxidant status. However, altered glucose-6-phosphate was seen only in the heart and brain and was not detectable in the plasma.
